H. B. Fuller Company (NYSE:FUL – Get Free Report)’s share price crossed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $51.49 and traded as high as $52.04. H. B. Fuller shares last traded at $51.52, with a volume of 666,160 shares trading hands.
Analyst Ratings Changes
Several research firms have recently issued reports on FUL. UBS Group reduced their price target on H. B. Fuller from $69.00 to $55.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 21st. JPMorgan Chase & Co. dropped their price objective on H. B. Fuller from $67.00 to $66.00 and set an “overweight” rating for the company in a report on Monday, September 28th. Deutsche Bank Aktiengesellschaft dropped their price objective on H. B. Fuller from $72.00 to $62.00 and set a “buy” rating for the company in a report on Tuesday, September 29th. Zacks Research lowered H. B. Fuller from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 18th. Finally, Weiss Ratings cut H. B. Fuller from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, September 14th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $62.88.
Check Out Our Latest Report on FUL
H. B. Fuller Stock Up 3.7%
The company has a current ratio of 1.82, a quick ratio of 1.10 and a debt-to-equity ratio of 0.95. The firm’s fifty day moving average price is $51.49 and its 200-day moving average price is $58.23. The company has a market cap of $2.77 billion, a price-to-earnings ratio of 14.35, a price-to-earnings-growth ratio of 0.61 and a beta of 0.99.
H. B. Fuller (NYSE:FUL – Get Free Report) last issued its quarterly earnings data on Thursday, September 24th. The specialty chemicals company reported $1.52 EPS for the quarter, topping the consensus estimate of $1.47 by $0.05. The business had revenue of $938.17 million for the quarter, compared to the consensus estimate of $945.59 million. H. B. Fuller had a return on equity of 12.65% and a net margin of 5.56%. The firm’s revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the business posted $1.26 EPS. Sell-side analysts predict that H. B. Fuller Company will post 4.88 earnings per share for the current year.
H. B. Fuller Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 29th. Stockholders of record on Thursday, October 15th were issued a dividend of $0.2450 per share. This represents a $0.98 annualized dividend and a dividend yield of 1.9%. The ex-dividend date was Thursday, October 15th. H. B. Fuller’s payout ratio is 27.30%.
Insiders Place Their Bets
In other H. B. Fuller news, Director Teresa Rasmussen bought 2,042 shares of the stock in a transaction that occurred on Monday, September 28th. The stock was acquired at an average cost of $48.96 per share, with a total value of $99,976.32. Following the purchase, the director owned 4,053 shares in the company, valued at $198,434.88. This trade represents a 101.54% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Thomas Handley purchased 2,000 shares of the business’s stock in a transaction on Monday, September 28th. The stock was bought at an average cost of $49.41 per share, for a total transaction of $98,820.00. Following the purchase, the director owned 2,000 shares of the company’s stock, valued at approximately $98,820. This represents a ? increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired 13,061 shares of company stock worth $646,340 in the last three months. 1.83% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On H. B. Fuller
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP raised its stake in shares of H. B. Fuller by 5.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,608,006 shares of the specialty chemicals company’s stock valued at $160,854,000 after purchasing an additional 132,558 shares during the period. Royal Bank of Canada boosted its position in shares of H. B. Fuller by 2,694.7% during the first quarter. Royal Bank of Canada now owns 675,765 shares of the specialty chemicals company’s stock worth $41,681,000 after buying an additional 651,585 shares during the period. Bank of America Corp DE boosted its position in shares of H. B. Fuller by 36.3% during the first quarter. Bank of America Corp DE now owns 513,163 shares of the specialty chemicals company’s stock worth $31,652,000 after buying an additional 136,666 shares during the period. Bank of New York Mellon Corp bought a new position in shares of H. B. Fuller during the second quarter worth about $29,611,000. Finally, Gamco Investors INC. ET AL grew its holdings in shares of H. B. Fuller by 0.9% during the first quarter. Gamco Investors INC. ET AL now owns 391,252 shares of the specialty chemicals company’s stock worth $24,132,000 after buying an additional 3,522 shares in the last quarter. 95.93% of the stock is currently owned by institutional investors and hedge funds.
About H. B. Fuller
H.B. Fuller Company (NYSE:FUL) develops and manufactures specialty adhesives, sealants and other engineered bonding solutions. Its products are used to assemble, protect, package and improve the performance of products across a wide range of industries, including construction, transportation, electronics, consumer goods, packaging and hygiene.
The company offers technologies such as hot-melt, water-based, reactive and pressure-sensitive adhesives, as well as sealants, coatings and related materials.
Recommended Stories
- Five stocks we like better than H. B. Fuller
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AIāThese 5 Stocks Are Getting Paid
Receive News & Ratings for H. B. Fuller Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. B. Fuller and related companies with MarketBeat.com's FREE daily email newsletter.
